US 2016/0243320 A1 · DRY POWDER INHALER

Abstract

This invention provides a dry powder inhaler comprising: a dry powder medicament comprising fluticasone propionate, salmeterol xinafoate and a lactose carrier; wherein, the delivered dose of salmeterol per actuation is less than 50 μg; and wherein the dose provides a baseline-adjusted FEV1 in a patient of more than 150 mL within 30 minutes of receiving the dose. A method of treating a patient includes administering to a patient a dry powder medicament having fluticasone propionate, salmeterol xinafoate and a lactose carrier; wherein, the delivered dose of salmeterol per actuation is less than 50 μg; and wherein the dose provides a baseline-adjusted FEV1 in a patient of more than 150 mL within 30 minutes of receiving the dose.

Claims20

Dependent claims

A dry powder inhaler comprising:

a dry powder medicament comprising fluticasone propionate, salmeterol xinafoate and a lactose carrier;
wherein, the delivered dose of salmeterol per actuation is less than 50 μg;
and
wherein the dose provides a baseline-adjusted FEV1 in a patient of more than 150 mL within 30 minutes of receiving the dose.

1 more element

Dependencies are inferred from the claim text.

Facts

Application

15/027,660Filed 6 Oct 2014

Priority

7 Oct 2013

Published

25 Aug 2016

Term ends

Not estimatedThe source records don’t support an estimate.

Classification24 codes

A61M 15/0008
Using rotating means: rotating by airflow
A61K 9/0075
Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy: for inhalation via a dry…
A61K 9/1623
Organic compounds, e.g. phospholipids, fats: sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
A61K 31/137
Having aromatic rings , e.g. ketamine, nortriptyline: arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone

Dry powder inhaler

Life of this patent

Dry powder inhaler

Life of this patent

Abstract

Claims20